Moderate to Severe Atopic Dermatitis Study
Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
SEX AT BIRTH: All
CONDITION: Atopic Dermatitis (Eczema)
LOCATION: UH Cleveland Medical Center
The purpose of this study is to evaluate the impact of lebrikizumab on vaccine responses (TDaP and meningococcal) in patients with moderate-to-severe Atopic Dermatitis. This study will further assess the efficacy and safety of lebrikizumab in patients with AD.
Who Can Participate
Participants between 18-55 years old with moderate to severe atopic dermatitis (eczema) and have not had a TDaP or meningococcal vaccines in the last 5 years may be eligible for this study.